Compass Pathways plc Depositary Receipt (5Y6)
XDUS
Closed
Aug 25, 2026
Day's Range
11.9052 wk Range
3.72Overview - 5Y6 - Compass Pathways plc Depositary Receipt
Key Statistics
Valuation
Enterprise Value
-114.57M
P/E (Trailing)
‪-3.86‬
PEG Ratio
‪-0.01‬
Price / Book
‪19.01‬
EV / EBITDA
‪0.68‬
Profitability
Return on Assets
‪-136.84%‬
Return on Equity
‪544.69%‬
Ownership
Shares Outstanding
134.94M
Price stats
50-Day Avg
‪11.09‬
200-Day Avg
‪7.60‬
Peers - 5Y6 - Compass Pathways plc Depositary Receipt
Peer Comparison
Compared with companies in Medical Care Facilities listed on XDUS.
- 5Y6XDUSCompass Pathways plc Depositary Receipt+66.05%52-week change-3.86P/E (Trailing)—Profit Margin
- HTHTWXDUSHTW+41.88%52-week change21.47P/E (Trailing)‪7.90%‬Profit Margin
- LIKXDUSLimes Schlosskliniken AG+39.46%52-week change29.06P/E (Trailing)‪11.39%‬Profit Margin
- 5XEXDUSExtendicare Inc.+57.22%52-week change16.43P/E (Trailing)—Profit Margin
- EIFXDUSMednation AG+49.47%52-week change3.53P/E (Trailing)‪87.85%‬Profit Margin
- 7ATXDUSAttendo AB (publ)+42.67%52-week change1.94P/E (Trailing)‪45.31%‬Profit Margin
- HCQXDUSAmn Healthcare Services Inc.+38.97%52-week change-11.69P/E (Trailing)‪28.34%‬Profit Margin
Profile Summary - 5Y6 - Compass Pathways plc Depositary Receipt
About
Compass Pathways plc Depositary Receipt represents shares in Compass Pathways plc, a biotechnology company focused on mental health innovation in the United Kingdom and the United States. The company develops COMP360, a proprietary investigational formulation of synthetic psilocybin therapy administered with…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
